Molecular diagnosis and combined lipid lowering therapy of heterozygous familial hypercholesterolemia. Report of one case;Hipercolesterolemia familiar heterocigota: Diagnóstico molecular y terapia combinada. Caso clínico

Revista Medica de Chile

Volumn 135, Issue 2, 2007, Pages 216-220

  Arteaga Ll, Antonio ^a   Cuevas M, Ada ^b   Rigotti R, Attilio ^a   González, Francisco ^c   Castillo, Sergio ^d   Mata L, Pedro ^e   Alonso K, Rodrigo ^e  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b CLÍNICA LAS CONDES   (Chile)

^c UNIVERSIDAD DE VALPARAÍSO   (Chile)

^d Laboratorio de Diagnóstico Genético Lácer   (Spain)

^e Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Ezetimibe; Hypercholesterolemia, familial combined; LDL receptor related proteins; Simvastatin

Indexed keywords

AZETIDINE DERIVATIVE; EZETIMIBE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; SIMVASTATIN;

ARTICLE; CASE REPORT; DNA MICROARRAY; DRUG EFFECT; FEMALE; GENETICS; HETEROZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; MIDDLE AGED; MUTATION; PROGNOSIS;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; FEMALE; HETEROZYGOTE; HUMANS; HYPERCHOLESTEROLEMIA; LDL-RECEPTOR RELATED PROTEINS; MIDDLE AGED; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SIMVASTATIN;

EID: 33947592022     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1: 445-66.
2. th ed. New York, NY: McGraw-Hill; 2001; 2863-2913.
3. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004; 160: 407-20.
4. Nervi F, Arteaga A, Maiz A, Tocornal J, Severin MC. Hipercolesterolemia familiar homocigota. Rev Méd Chile 1979; 107: 624-8.
5. Tejedor D, Castillo S, Mozas P, Jiménez E, López M, Tejedor MT et al. Spanish FH Group. Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 2005; 51: 1137-44.
6. The low density lipoprotein receptor database. http://www.ucl.ac.uk/fh/
7. Jeon H, Blacklow SC. Structure and physiologic function of the low-density lipoprotein receptor. Annu Rev Biochem 2005; 74: 535-462 ??
8. Miltiadus G, Xenophontos S, Bairaktari E, Ganotakis M, Cariolou M, Elisaf M. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Pharmacogenet Genomics 2005; 15: 219-25.
9. Naoumova RP, Thompson GR, Soutar AK. Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol 2004; 15: 413-22.
10. Murdoch D, Scott LJ. Ezetimibe/Simvastatin: a review of its use in the management of hypercholesterolemia. Am J Cardiovasc Drugs 2004; 4: 405-22.
11. Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L et al. Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004; 148: 447-55.
12. Kastelein JJ, Sager PT, De Groot E, Veltri E. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J 2005; 149: 234-9.
13. Gagne C, Gaudet D, Bruckert E. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105: 2469-75.
14. Yamamoto A, Harada-Shiba M, Endo M, Kusakabe N, Tanioka T, Kato H et al. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis 2006; 186: 126-31.
15. Hobbs HH, Graf GA, Yu L, Wilund KR, Cohen JC. Genetic defenses against hypercholesterolemia. Cold Spring Harb Symp Quant Biol 2002; 67: 499-505.